Gypsophila oldhamiana leaves as a potential industrial resource of lipids, alkaloids, flavonoids and anti-osteoporosis components

An updated overview of Gypsophila species: Phytochemical and pharmacological investigations

Medicinal plants and their consituents play a crucial role in disease prevention and treatment. The genus Gypsophila (Caryophyllaceae family), comprising approximately 150 species of flowering plants, holds significant value in both ornamental and therapeutic fields. Traditional uses in various cultures highlight their potential in treating a range of conditions, such as liver disorders, diabetes, and kidney stones. These resilient plants, known for their delicate blooms and adaptability to diverse environments, are rich in chemical compounds, including non-volatile constituents such as phenolic compounds (e.g., flavonoids), terpenoids, saponins, cyclopeptides, and alkaloids. Additionally, monoterpenes and sesquiterpenes, the primary volatile constituents, exhibit significant insecticidal properties. Gypsophila species show a broad spectrum of pharmacological effects, including hepatoprotective, cytotoxic, anti-diabetic, antioxidant, cytotoxic, anti-inflammatory, diuretic, neuroprotective, and anti-obesity properties. This review underscores the promising therapeutic potential of Gypsophila and advocates for further research, particularly clinical trials, to thoroughly assess their efficacy and safety. By consolidating existing knowledge, it sheds light on the potential of Gypsophila species as valuable resources for human health and underscores the need for continued exploration to uncover novel treatments and interventions.

Development of phytotherapeutic nanoformulation containing Gypsophila eriocalyx and its evaluation as a candidate formulation for osteoporosis treatment on human bone marrow stem cells

INTRODUCTION

Osteoporosis, one of the common bone diseases, manifests itself as a decrease in bone mass. Recently, the use of medicinal plants in the search for effective and low-toxicity therapeutics for the prevention or treatment of osteoporosis has become a trending topic.

OBJECTIVE

In this study, we aim to prepare a controlled drug carrier system loaded with Gypsophila eriocalyx to determine its potential for anti-osteoporosis applications.

METHODS

Gypsophila eriocalyx extract (GEE) was prepared, and components were determined. The molecular interactions of the components with Cathepsin K (CatK), which is used as a target in drug development against osteoporosis, were revealed by in silico molecular docking and MD methods. ADMET profiles were also examined. GEE-loaded chitosan nanoparticles (CNPs) were synthesized. The nanoparticles' morphology, encapsulation efficiency, loading capacity, release profile, average size, polydispersity index, and zeta potentials were determined. The cytotoxic effects of GEE and GEE-loaded CNPs on the L929 and osteogenic proliferation profiles on human bone marrow stem cells (hBMC) were examined.

RESULTS

The MD analysis revealed no breaks or atomic changes in the dynamic system, and the docking analysis confirmed the continued interaction of identical residues. It was determined that the GEE-loaded CNP formulation was produced successfully, had no toxic effect on the L929, and had an osteogenic proliferation effect on hBMC.

CONCLUSION

In line with the in vitro and in silico results obtained, it was evaluated that GEE-loaded CNPs can be used as a controlled drug release system as a candidate formulation with phytotherapeutic properties for osteoporosis treatment.q1.